Is Prothena Corporation plc (PRTA) overvalued? · rev $135.2M
Prothena Corporation plc (PRTA) is a biotechnology company listed on US.
This page asks whether Prothena Corporation plc (PRTA) looks expensive on cached numbers — not a short thesis.
Latest reported PRTA revenue for 2024-12-31 was $135.2M. Net income was -$122.3M. Revenue was up 47.9% from 2023-12-31 to 2024-12-31. PRTA currently screens at market cap $460.2M.
PRTA currently screens at market cap $460.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PRTA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PRTA stock page for the full model, not this heading.
Not investment advice.